Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

idelalisib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 48 Other hematologic neoplasm 37 Plasma cell 2 Gastrointestinal 2 Thoracic 1 Myeloid 1 Genitourinary 1 Classical hematology 1 Breast 1

Conditions

Recurrence 1 Neoplasm Metastasis 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1009 Cisplatin 786 Pemetrexed 724 pembrolizumab 537 Paclitaxel 516 Docetaxel 469 Gemcitabine 366 Radiotherapy 348 Erlotinib Hydrochloride 336 Bevacizumab 294 Nivolumab 291 Etoposide 259 durvalumab 235 Drug Therapy 218 osimertinib 204 atezolizumab 192 Radiosurgery 165 Gefitinib 162 Vinorelbine 134 Magnetic Resonance Spectroscopy 118 130-nm albumin-bound paclitaxel 109 Ipilimumab 106 Cetuximab 97 Topotecan 92 Surgical Procedures, Operative 90 Cyclophosphamide 90 Specimen Handling 88 Blood Specimen Collection 86 tislelizumab 85 anlotinib 83

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03257722 2024-02-28

PIL

Augusta University

Phase 1/2 Terminated

4 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡